Journal
VIRUSES-BASEL
Volume 15, Issue 8, Pages -Publisher
MDPI
DOI: 10.3390/v15081674
Keywords
rabies; lyssavirus; virus attenuation; PEP; antibody; scFv; rabies treatment
Categories
Ask authors/readers for more resources
The rabies virus is responsible for over 59,000 human deaths per year and is difficult to treat in endemic areas. To overcome this, researchers developed a live-attenuated recombinant rabies virus expressing a highly neutralizing antibody linked to a fluorescent marker. This approach shows promise for the development of a therapeutic live-attenuated virus-based treatment for rabies infection.
Rabies virus (RABV) causes possibly the oldest disease and is responsible for an estimated >59,000 human fatalities/year. Post exposure prophylaxis (PEP), the administration of vaccine and rabies immunoglobulin, is a highly effective tool which is frequently unavailable in RABV endemic areas. Furthermore, due to the constraints of the blood-brain barrier, current PEP regimes are ineffective after the onset of clinical symptoms which invariably result in death. To circumvent this barrier, a live-attenuated recombinant RABV expressing a highly RABV-neutralising scFv antibody (62-71-3) linked to the fluorescent marker mCherry was designed. Once rescued, the resulting construct (named RABV-62scFv) was grown to high titres, its growth and cellular dissemination kinetics characterised, and the functionality of the recombinant 62-71-3 scFv assessed. Encouraging scFv production and subsequent virus neutralisation results demonstrate the potential for development of a therapeutic live-attenuated virus-based post-infection treatment (PIT) for RABV infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available